Nutrition additive supply chains 'nervous' as Suez blockage continues
Some seaborne deliveries are being rerouted or switched to air transportation as efforts to re-float stricken Ever Given container vessel move into fourth day
The logjam in the Suez canal caused by a stricken container ship wedged across the vital trade route has caused nervousness to human and animal nutrition additive supply chains, with some deliveries being switched to air transportation or put on hold, according to online trade platform and data provider, Kemiex.
Earlier this week, the 200,000-ton Panama-registered Ever Given, operated by shipping company Evergreen and bound for Rotterdam in the Netherlands from China became stuck in the Egyptian canal.
Efforts to re-float the vessel and free up the waterway are ongoing.
Stefan Schmidinger, partner at Kemiex told CPHI Online that three days after the incident, it remains unclear how long the waterway will be affected, with the best case scenario being a resolution next week, “but if cargo needs to be unloaded first this would multiply to three to six weeks in a base case.”
According to ship tracking platforms, an increasing number of vessels have changed course to take the route around Africa, causing a one-week delay to arrive at their destination, and a two-week delay for a full Asia-Europe round trip.
Schmidinger said this course of action results in a 10-20% reduction of carrier and container capacity on this lane, as well as additional fuel consumption and emissions, in a freight market that has been operating at its limits amid record rates for the last year.
“Human and animal nutrition additives, as well as other bulk chemicals, are being impacted directly, causing significant nervousness among supply chain managers,” he said. “A few new factory deliveries have reportedly been re-booked to air as the additional cost was secondary to a timely delivery, but more shippers have rushed to secure space or even put April deliveries on-hold.”
Schmidinger said the bottleneck could prove to be a boost to ‘niche’ freight trains connecting China-Europe typically costing less than air but moving cargo faster than sea.
Container freight rates have spiralled over the last few months amid a shortage of containers in Asia as Chinese exports recovered from the effects of the coronavirus pandemic. The Freightos FBX11 China-North Europe route index was marked at $7,500/FEU on March 25, up from around $2,500/FEU in November.
Schmidinger confirmed that as pharmaceutical ingredients are mostly airborne, the Suez incident has yet to cause any supply disruption for the sector.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance